Literature DB >> 19185022

Ginsenosides protect striatal neurons in a cellular model of Huntington's disease.

Jun Wu1, Hye Kyoung Jeong, Sarah Elizabeth Bulin, Sung Won Kwon, Jeong Hill Park, Ilya Bezprozvanny.   

Abstract

Ginseng, the root of Panax ginseng C.A. Meyer (Araliaceae), is a widely used herbal medicine. Ginsenosides, the active ingredients of ginseng, are the main components responsible for many beneficial actions of ginseng. In the present study, we tested 10 different ginsenosides in the previously developed in vitro Huntington's disease (HD) assay with primary medium spiny striatal neuronal cultures (MSN) from the YAC128 HD mouse model. We found that nanomolar concentrations of ginsenoside Rb1 and Rc effectively protected YAC128 medium spiny neurons from glutamate-induced apoptosis and that Rg5 was protective at micromolar concentration. The other seven ginsenosides tested were not effective or exerted toxic effects in MSN cultures. From further experiments, we suggested that neuroprotective effects of ginsenosides Rb1, Rc, and Rg5 could correlate with their ability to inhibit glutamate-induced Ca(2+) responses in cultured MSN. From these results we concluded that ginsenosides Rb1, Rc, and Rg5 offer a potential therapeutic choice for the treatment of HD and possibly other neurodegenerative disorders. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19185022      PMCID: PMC2792727          DOI: 10.1002/jnr.22017

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  38 in total

1.  Protective effects of ginseng saponins on 3-nitropropionic acid-induced striatal degeneration in rats.

Authors:  Jong-Hoon Kim; Sunoh Kim; In-Soo Yoon; Jong-Hwan Lee; Byung-Jun Jang; Sang Min Jeong; Jun-Ho Lee; Byung-Hwan Lee; Jin-Soo Han; Sekwan Oh; Hyung-Chun Kim; Tae Kyu Park; Hyewhon Rhim; Seung-Yeol Nah
Journal:  Neuropharmacology       Date:  2005-04       Impact factor: 5.250

2.  Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease.

Authors:  V Macdonald; G M Halliday; R J Trent; E A McCusker
Journal:  Neuropathol Appl Neurobiol       Date:  1997-12       Impact factor: 8.090

3.  Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95.

Authors:  Y Sun; A Savanenin; P H Reddy; Y F Liu
Journal:  J Biol Chem       Date:  2001-04-23       Impact factor: 5.157

4.  Upregulation of preprodynorphin and preproenkephalin mRNA expression by selective activation of group I metabotropic glutamate receptors in characterized primary cultures of rat striatal neurons.

Authors:  L Mao; J Q Wang
Journal:  Brain Res Mol Brain Res       Date:  2001-01-31

5.  Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease.

Authors:  Jacqueline Shehadeh; Herman B Fernandes; Melinda M Zeron Mullins; Rona K Graham; Blair R Leavitt; Michael R Hayden; Lynn A Raymond
Journal:  Neurobiol Dis       Date:  2005-09-13       Impact factor: 5.996

6.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

7.  Herbal products and serious side effects: a case of ginseng-induced manic episode.

Authors:  I Vázquez; L F Agüera-Ortiz
Journal:  Acta Psychiatr Scand       Date:  2002-01       Impact factor: 6.392

8.  Three new dammarane glycosides from heat processed ginseng.

Authors:  Il Ho Park; Na Young Kim; Sang Beom Han; Jong Moon Kim; Sung Won Kwon; Hyun Jung Kim; Man Ki Park; Jeong Hill Park
Journal:  Arch Pharm Res       Date:  2002-08       Impact factor: 4.946

9.  Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release.

Authors:  Yeun Su Choo; Gail V W Johnson; Marcy MacDonald; Peter J Detloff; Mathieu Lesort
Journal:  Hum Mol Genet       Date:  2004-05-26       Impact factor: 6.150

10.  Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease.

Authors:  Xiaofeng Gu; Véronique M André; Carlos Cepeda; Shi-Hua Li; Xiao-Jiang Li; Michael S Levine; X William Yang
Journal:  Mol Neurodegener       Date:  2007-04-30       Impact factor: 14.195

View more
  27 in total

1.  Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

Authors:  Xuesong Chen; Jun Wu; Yuan Luo; Xia Liang; Charlene Supnet; Mee Whi Kim; Gregor P Lotz; Guocheng Yang; Paul J Muchowski; Thomas Kodadek; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-09-23

2.  Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment.

Authors:  Jun Wu; Hsin-Pei Shih; Vladimir Vigont; Lori Hrdlicka; Len Diggins; Carol Singh; Matt Mahoney; Richard Chesworth; Gideon Shapiro; Olga Zimina; Xuesong Chen; Qingqing Wu; Lyubov Glushankova; Michael Ahlijanian; Gerhard Koenig; Galina N Mozhayeva; Elena Kaznacheyeva; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-06-24

3.  Ginsenoside-Rd attenuates TRPM7 and ASIC1a but promotes ASIC2a expression in rats after focal cerebral ischemia.

Authors:  Yunxia Zhang; Linfu Zhou; Xiao Zhang; Jiuxu Bai; Ming Shi; Gang Zhao
Journal:  Neurol Sci       Date:  2012-01-10       Impact factor: 3.307

4.  Ginsenoside Rb1 Prevents MPP(+)-Induced Apoptosis in PC12 Cells by Stimulating Estrogen Receptors with Consequent Activation of ERK1/2, Akt and Inhibition of SAPK/JNK, p38 MAPK.

Authors:  Ryo Hashimoto; Jing Yu; Hideki Koizumi; Yasuyoshi Ouchi; Tetsuro Okabe
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-16       Impact factor: 2.629

5.  Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.

Authors:  Jun Wu; Daniel A Ryskamp; Xia Liang; Polina Egorova; Olga Zakharova; Gene Hung; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2016-01-06       Impact factor: 6.167

6.  Therapeutic potential of ginsenoside Rg3 and Rf for Huntington's disease.

Authors:  Mijung Lee; Jae-Jun Ban; Bo Hee Won; Wooseok Im; Manho Kim
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-06-14       Impact factor: 2.416

Review 7.  Pharmacological activities of ginsenoside Rg5 (Review).

Authors:  Ming-Yang Liu; Fei Liu; Yan-Li Gao; Jia-Ning Yin; Wei-Qun Yan; Jian-Guo Liu; Hai-Jun Li
Journal:  Exp Ther Med       Date:  2021-06-06       Impact factor: 2.447

8.  Effects of Panax ginseng in Neurodegenerative Diseases.

Authors:  Ik-Hyun Cho
Journal:  J Ginseng Res       Date:  2012-10       Impact factor: 6.060

9.  A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system.

Authors:  Hee Jin Kim; Pitna Kim; Chan Young Shin
Journal:  J Ginseng Res       Date:  2013-03       Impact factor: 6.060

10.  Anti-inflammatory effect of ginsenoside Rg5 in lipopolysaccharide-stimulated BV2 microglial cells.

Authors:  Yu Young Lee; Jin-Sun Park; Ji-Sun Jung; Dong-Hyun Kim; Hee-Sun Kim
Journal:  Int J Mol Sci       Date:  2013-05-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.